Journal article
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Wanling Xie, Meredith M Regan, Marc Buyse, Susan Halabi, Philip W Kantoff, Oliver Sartor, Howard Soule, Noel W Clarke, Laurence Collette, James J Dignam, Karim Fizazi, Wendy R Paruleker, Howard M Sandler, Matthew R Sydes, Bertrand Tombal, Scott G Williams, Christopher J Sweeney
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2017
Abstract
Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By June 2013, 102 completed or ongoing randomized trials were identified and individual patient data were collected from 28 trials with 28,905 patients. Disease-free survival (DFS) and metastasis-free survival (MFS) were determined for 21,140 patients from 24 trials and 12,712 patients from 19 trials, respectively. We evaluated the surrogacy of DFS and MFS for OS by using a two-stage meta-analytic validation model by determining the correlation of an interm..
View full abstractGrants
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Awarded by Medical Research Council
Funding Acknowledgements
Funded by the Prostate Cancer Foundation Challenge Award and grants from Astellas Pharma, Medivation, Janssen Pharmaceuticals, Millennium Pharmaceuticals, Sotio, and Sanofi.